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Abstract: 
 
Systemic lupus erythematosus (SLE) is a chronic autoimmune condition with unpredictable 
course, intermingled with flares and periods of remission. Although the prognosis of the 
disease has improved in the past decades, current therapies are still associated with 
treatment-related complications. Recently, there has been major progress in the 
understanding of the pathogenesis of SLE, paving the way for the development of new 
biological agents, potentially revolutionising the treatment of SLE. 
 
This review summarizes available data on novel biological therapies for SLE, focusing on 
recent results from clinical trials. 
 
As a result of treatment strategies based upon individualized therapeutic approach, it is 
hoped that the clinical view of SLE will change from a severe autoimmune disease to a 
condition in which significant damage, mortality and treatment related complications can 
be prevented in the majority of SLE patients. 
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Introduction: 
 
 
 
 
Systemic lupus erythematosus (SLE) is an autoimmune condition heterogeneous from 
clinical and immunological point of view, with variable and unpredictable course, 
intermingled with periods of flares and remission. For decades, the therapy for SLE has 
been based on glucorticosteroids, hydroxychloroquine, and the immunosuppressive 
agents[1]. These approaches have been related to a remarkable improvement in the 
prognosis of SLE. However, the occurrence of refractory disease and adverse effects 
related to conventional therapies such as glucocorticoids and the cytotoxic agents sill 
represent a challenge for physician, requiring the development of more efficacious 
treatments with higher safety profile in SLE. Rituximab and, more recently, belimumab are 
the most extensively used biological agents in SLE. 
 
Although the results of two randomized controlled trials suggest that the use of Rituximab 
in SLE may be controversial, it is still extensively used ‘off label’, especially in refractory 
cases to standard treatment. Belimumab has been the first biological agent approved by 
the Food and Drug agency (FDA) for the treatment of active SLE in addition to standard of 
care [1, 2]. Despite the initial enthusiasm related to the approval of a tailored approach for 
SLE treatment, there are still uncertainties on the selection of the ideal patient that might 
benefit from this agent and the optimal duration of therapy [3, 4]. 
 
In the last years, an increasing number of new biological therapies have being tested in 
SLE with heterogeneous results. 
 
The current goal of development of novel biological agents for SLE is to identify therapies 
that are potentially more effective than conventional approaches and at the same time are 
able to reduce the risk of organ damage and therapy-induced side effects. This review 
summarizes available data on novel upcoming biological therapies for SLE, beyond 
rituximab and belimumab, focusing on recent results from clinical trials (Table 1). 
  
B-cell targeted therapies 
 
B cells can be selectively targeted for depletion either via direct B cell surface molecules 
CD19 and CD20 (Rituximab, Ocrelizumab) and CD22 (Epratuzumab) or by inhibition of B 
cell survival factors BLyS (Belimumab) and APRIL (Atacicept) [3]. 
 
It is out of the scope of this review to explore the clinical efficacy of Rituximab in SLE since 
this has been extensively discussed elsewhere [5]. However, due this topic is worthy some 
considerations. 
 
The use of rituximab in patients with SLE has been investigated in two randomised 
controlled trials, EXPLORER (The Exploratory Phase II/III SLE Evaluation of Rituximab)[6] 
and LUNAR (Lupus Nephritis Assessment With Rituximab)[7] with negative results 
regarding superiority to conventional treatment. However, before concluding that 
Rituximab is not effective in SLE, a critical evaluation of the design of the EXPLORER and 
LUNAR trials is required. Firstly, a high percentage of patients included were likely to have 
had mild to moderate SLE (especially in the EXPLORER trial) with no history of poor 
response to conventional therapies. This fact, in itself, may potentially justify why 
Rituximab was not superior to the other therapies in this setting. Secondly, considering 
concomitant therapies, very high doses of corticosteroids were permitted in both arms of 
these trials, leading to significant differences not being evident in a short-term follow-up. 
Thirdly, some authors have speculated a possible synergistic effect of Rituximab in 
combination with immunosuppressive agents (cyclophosphamide or mycophenolate)[8] but 
this aspect was not evaluated in these RCTs. Fourthly, LUNAR and EXPLORE included 
different sub sets of patients (mainly North and Central-South American patients) when 
compared to the majority of patients from uncontrolled studies (European). This 
observation about ethnicity might be considered as a variable therapeutic response to the 
different immunosuppressive agents [9]. 
Finally, and most importantly, aiming to prove the superiority of Rituximab over current 
first-line therapies in SLE (corticosteroids, cyclophosphamide, and mycophenolate) does 
not reflect the use of Rituximab in clinical practice, where rituximab is mainly considered in 
refractory cases to these therapies. 
 
Ocrelizumab 
 
Ocrelizumab is a humanized anti-CD20 monoclonal antibody. When compared to 
rituximab, ocrelizumab may have a safer profile in term of immunogenicity and 
complement activation, theoretically leading to a reduced frequency of adverse infusion 
reactions and the development of drug neutralizing antibodies. 
 
BEGIN and renal BELONG are two phase III RCTs investigating the efficacy of 
ocrelizumab in non-renal and renal SLE respectively [10]. Ocrelizumab was given at 
different doses (400 or 1000 mg intravenously) on day 1 and day 15. A repeat single 
dosing was administered every 4 months. The BEGIN study was interrupted early when 
the decision was made that ocrelizumab was not likely to benefit patients with active SLE. 
In the BELONG a total of 381 patients were recruited to investigate the efficacy of 
ocrelizumab in patients with proliferative lupus nephritis (class III/IV) on top of high-dose 
glucocorticoids and either MMF or CYC (according to the Euro-lupus protocol). The trial 
was terminated early because of the higher rate of serious infections in patients receiving 
ocrelizumab compared to placebo (mainly in those receiving ocrelizumab and MMF). 
However, in patients who had passed the 32-week treatment point (223/381), the overall 
renal response in the ocrelizumab arm was (67%) was not significantly higher than that of 
placebo (67% Vs. 55%) [11]. 
 
 
Anti-CD22 
 
Epratuzumab 
Epratuzumab is a humanised monoclonal antibody targeting the CD22 surface receptor on 
mature B cells [12]. 
 
Two randomized placebo-controlled trials (ALLIVIATE 1 and ALLIVIATE 2, 14 and 90 
recruited patients, respectively) investigating the use of epratuzumab in addition to 
standard of care in SLE patients with moderate to severe activity reported a clinical 
improvement compared to placebo [13]. Epratuzumab was well tolerated without severe 
adverse events. However, these studies were terminated because of the disruption of drug 
supply [14]. 
 
Subsequently, ENBLEM, a more recent Phase IIb RCT (trial not powered for significance) 
in 227 SLE patients with moderate to severe disease activity (excluding severe 
neuropsychiatric and renal disease showed that the proportion of responders was higher in 
all epratuzumab groups than with placebo. A post hoc analyses showed that a cumulative 
dose of 2400 mg of epratuzumab was associated with a significantly better clinical 
improvement. The frequencies of AEs and SAEs, including infusion reactions, were not 
different across all groups of patients [15]. 
 
These promising results have lead to two phase III RCTs (EMBODY 1 and 2), aiming to 
investigate the clinical efficacy of Epratuzumab in the treatment of patients with moderate 
to severe SLE, in addition to conventional treatment [12]. 
 
 
B Lymphocyte Stimulator (BLyS) and A Proliferation Inducing Ligand (APRIL) 
targeted therapy 
 
 
 
 
 
Belimumab 
 
Belimumab is an fully humanized IgG1 monoclonal antibody that specifically binds to 
soluble trimeric BLyS and inhibiting its activity [16]. The clinical efficacy and safety of this 
new agent have been tested in two RTC, BLISS-52 [2] and BLISS-76 [17]. Together, the 
two trials included 1684 lupus patients with mild to moderate disease activity (excluding 
renal or CNS involvment). In the BLISS-52 study [2], a beneficial effects of belimumab 
were noted using the SLE responder index (SRI) with the belimumab 10 mg/kg, with the 
difference being apparent at week 16. In the BLISS-76 study, the belimumab 10 mg/kg 
group also met the primary efficacy end point at week 52 (SRI rate 43.2 vs 33.5% in 
placebo; p = 0.02) [17]. Both RTCs demonstrated a significant improvement in disease 
outcome with 10mg/kg of Belimumab when compared to placebo in terms of the 
cumulative risk of disease flares and time to first flare [17, 18]. 
 
Post hoc analyses of the two BLISS RTCs demonstrated that patients with SELENA-
SLEDAI > 10, low complement, anti-dsDNA positivity or corticosteroid use at baseline had 
greater benefit from belimumab (measured at week 52 by SRI) when compare to placebo 
and to those without these characteristics [19]. Secondary end points such as severe 
disease flares, corticosteroid sparing effect, improvement in fatigue, and health-related 
quality of life also showed greater effects in the low complement/anti-dsDNA positive 
subgroup of belimumab-treated patients. Patients with renal, neurologic, or vasculitic 
involvement, elevated anti-dsDNA or BLyS levels, or low C3 at baseline had increased risk 
of disease flare over 1 year 
 
Results from BLISS-52 and BLISS-76 supported the use of Belimumab in the treatment of 
SLE and in 2011 Belimumab was approved by the FDA and EMA and has become the first 
drug approved for SLE for over 50 years [19]. 
 
The results remain positive with a maintained reduction in corticosteroid use and low rates 
of adverse effects in a seven-year follow up of lupus patients treated with belimumab [20]. 
A 70%-decline from baseline in autoantibodies to dsDNA at 7 years after treatment was 
also observed. 
 
Taken  the  above  together,  these  results  suggest  that  targeting  BLyS  with  the  novel 
biologic Belimumab can provide significant clinical benefit to SLE patients and is well 
tolerated long-term. However, few considerations are necessary. Belimumab has not been 
invesigated and is not indicated in patients with severe active neuropsychiatric lupus and 
lupus nephritis (proteinuria > 6 g/day; serum creatinine ‡ 2.5 mg/dl; recent hemodialysis). 
Indeed, less than 6% of SLE patients in BLISS-52 and BLISS-72 had proteinuria of >2 
g/day. A post hoc analysis on 267 (16%) SLE patients with renal disease showed that 
numerically more patients treated with belimumab had improvement in proteinuria and 
renal remission when compared to placebo, especially to receiving MMF or with 
serological activity [21]. However, interpretation of the results should be taken with 
cautions due to the small number of patients. A new study of belimumab in lupus nephritis 
is in progress (BLISS-LN) (NCT01639339) 
 
 
 
Tabalumab and Blisibimod 
 
Owing the recent FDA and EMEA approval for belimumab, two further anti-BLyS agents 
are currently being assessed in a phase III RCT to evaluate their benefit in the treatment of 
SLE[22, 23]. 
 
Blisibimod (A-623) is a fusion protein between the Fc portion of IgG and four BAFF-binding 
domains peptide that selectively binds to BLyS. It is a subcutaneous potent BAFF inhibitor 
agent. High dose Blisibimod (200mg once weekly) produced significantly higher responder 
rates (measured as ≥7 or ≥8 point reduction in SLEDAI) when compared to placebo in a 
phase II trial (PEARL-SC). Moreover, a subset of severe to moderate lupus patients 
showed an even greater improvement with 41.7% responder rate achieving either ≥7 or ≥8 
 
SLEDAI point decrease in the high dose blisibimod group compared to placebo (p = 0.002, 
p < 0.001 respectively). Similarly, normalization of biomarker of SLE activity (decrease in 
anti-ds DNA (p < 0.001) and increase in C3 (p < 0.01) and C4 (p < 0.001)) was observed 
in the blisibimod group [24]. The drug was well tolerated at all doses with no increase in 
the incidence of infections and SAEs. A Phase III clinical trial is in progress (CHABLIS-
SC1-NCT01395745). 
 
Tabalumab (LY2127399) is a fully humanized monoclonal antibody directed against both 
soluble and membrane bound BLyS. Clinical efficacy of tabalumab in patients with active 
rheumatoid arthritis (RA) with an inadequate response to methotrexate but naıve to 
biological therapy was assed in a phase II randomized controlled trial. Despite the 
promising early results in RA, it has been announced that further development of 
Tabalumab in SLE would be discontinued due to insufficient efficacy [25] in two phase III 
RCTs (ILLUMINATE 1 and ILLUMINATE 2) [25, 26]. In brief, in the ILLUMINATE 1 study, 
Tabalumab did not achieve the primary endpoint (significant improvement on SLE 
Responder Index-5), at either dose studied. In ILLUMINATE 2, the higher dose of 
Tabalumab met this endpoint. However, collectively, the data from ILLUMINATE 1 and 2 
did not meet the producer’s expectations for efficacy in the context of existing treatments. 
 
It is worth mentioning the overall safety profile showed a similar frequency of adverse 
events in patients treated with either Tabalumab or conventional treatment. 
 
 
Atacicept 
 
Atacicept is a recombinant fusion protein consisting in the TACI receptor that binds both 
BLyS and APRIL fused with the Fc portion of IgG. In a phase I RCT 49 mild to moderate 
SLE patients treated with Atacicept showed an attenuation in mature B cells and dose 
dependent decreases in autoantibody levels, when compared to placebo [27]. However, 
despite the early positive expectations, a phase I/II RCT of Atacicept in patients with lupus 
nephritis was prematurely terminated due to safety concerns [28]. 
T cell targeted therapies 
 
Edratide 
 
Edratide is a tolerogenic peptide based on the sequence of the first complementarity-
determining (CDR1) region of a anti-DNA monoclonal antibody (16/6 idiotype). Preliminary 
studies in humans confirmed data from animal models showing that edratide 
downregulates pathogenic cytokines and apoptosis, IFN-a gene expression, and 
upregulates immunosuppressive molecules and Tregs cells in peripheral blood [29-31]. 
However, a 24-week Phase II study of 340 SLE patients failed to achieve the primary end 
point of a reduction in SLEDAI-2K scores was and was prematurely interrupted [32]. 
 
 
Rigerimod (Lupuzor) 
 
Rigerimod is peptide that binds MHC class II. Although its mechanism of action remains 
not fully understood, preliminary data showed that rigerimod blocks inappropriate T-cell 
reactivity to MHC-presented self-peptides, resulting in restoring immune tolerance [33, 34]. 
Twenty patients with active SLE were treated with 2-weekly subcutaneous injection of 
rigerimod (200 μg) in an early Phase IIa study. Rigerimod was well tolerated and an 
improvement of disease activity and a reduction in anti-dsDNA titers were observed [35]. 
Similar results were obtained in a subsequent Phase IIb randomized placebo-controlled 
trial involving 136 SLE patients, showing a a significantly higher SRI than placebo at week 
12 (62 vs 39%) [36]. Further studies are currently ongoing. 
 
 
Laquinimod 
 
Laquinimod has been originally investigated in the treatment of relapsing-remitting multiple 
sclerosis [37]. Laquinimod downregulates the pro-inflammatory cytokines (IL-6, IL-12, IL-
17, IL-23, and TNF-a) but increases the production of IL-10, exerting an 
immunomodulating effects on antigen presenting cells that direct T cells. 
Preliminary results from a Phase IIa randomized placebo-controlled study including 46 
patients with active lupus nephritis showed that association of laquinimod (0.5 mg and 1.0 
mg/day) to MMF and corticosteroid had an additive effect in improving renal function and 
proteinuria [38]. No increase in side effect was seen, paving the way for further 
investigation. 
 
 
Toleragen molecule 
 
Abetimus sodium (LJP394) 
 
Abetimus sodium is an intravenously administered tetrameric oligonucleotide conjugate 
that tolerizes B-cells by cross-linking antidouble-stranded DNA antibodies receptors on 
their cell surfaces and triggering the signal transduction pathways inducing B-cell to 
anergy or apoptosis. Given the importance of anti-dsDNA antibodies in the pathogenesis 
of lupus nephritis, the Phase II and III trials were designed to evaluate whether treatment 
with abetimus sodium could prolong the time to renal flare in cohorts of patients at high 
risk of nephritic flares [39-41]. A preliminary placebo-controlled study showed a significant 
and persistent reduction of anti-dsDNA titers in lupus patients receiving the highest dose of 
abetimus. This observation was not associated with an increase risk of adverse events 
[41]. Following these positive results, a multicenter Phase II/III trial including 230 patients 
with lupus nephritis showed a significantly reduction in the number of renal flares and 
prolonged the time to renal flare at 76 weeks compared to placebo in a subset of patients 
with high-affinity serum IgG fraction for the DNA epitope of abetimus [42]. Nevertheless, 
these results were not confirmed in two subsequent Phase III trials including 317 and 943 
(ASPEN trail) SLE patients respectively. Abetimus (either at the dose of 100 mg/week or 
900 mg/week) did not reach the studies’ outcome in terms of prolonging the time to renal 
flare, the need for rescue immunosuppressive therapy, or the time to major SLE flares as 
compared to placebo [43, 44]. 
 
  
Targeting proteasomes 
 
 
In 2001, Fröhlich and co-workers [45] reported the first case of the successful use of twice-
weekly bortezomib, a proteasome inhibitor in a patient with SLE and concomitant multiple 
myeloma, proving clinical support to the preliminary evidence of the efficacy of bortezomib 
in mouse models of lupus. 
 
However, the high incidence of neurological, gastrointestinal, and hematological side 
effects related to bortezomib still represent the major limiting factor for further studies with 
this drug in SLE. 
 
Recently, different scheme (once-weekly regimen) have been proposed suggesting the 
possible usefulness of the of bortezomib therapy in SLE. This regimen has already been 
introduced in MM trials, leading to a decrease in haematological, gastrointestinal and 
neurological side effects, accompanied by a similar efficacy. Further studies are eagerly 
needed. 
 
 
Cytokine blockade targeted therapies 
 
Tocilizumab (anti-IL-6 receptor mAb) 
 
Tocilizumab is a humanised monoclonal antibody direct to IL-6 receptor. An open-label 
Phase I [46] study of tocilizumab in 16 SLE patients with mild to moderate showed an 
improvement in the SLEDAI score by > 4 points in more than half of the patients, as well 
as a reduction in anti-dsDNA levels. Indeed, arthritis improved in all patients suffering from 
this manifestation at baseline. 
 
However, it is worth noting that the infection rate was as high as 69% of patients. Further 
studies are warranted. 
Sirukumab (anti-IL-6 mAb) 
 
Sirukumab is also a humanised monoclonal antibody that binds to IL-6 and inhibits its 
biological activity. A Phase I placebo-controlled study in 46 patients with systemic or 
cutaneous lupus [47] showed a dose-independent reduction in total while cell, absolute 
neutrophil and platelet counts and minor elevation in total cholesterol levels. More recently, 
a phase II trial with sirukumab in lupus patients with lupus nephritis failed to prove an 
improvement in proteinuria. Moreover, infection rate was higher than expected, leading to 
the interruption of the trial. 
 
 
Sifalimumab (anti-interferon alpha (IFN-α)) 
 
Sifalimumab is a human IgG1 monoclonal antibody targeting IFN-α [48, 49]. A recent 
phase IIb trial showed that SLE patients treated with sifalimumab met the study primary 
endpoint by the SLE Responder Index (SRI-4) at Day 365. Clinical benefits in organ-
specific outcomes measures (joints, skin) was also observed [50]. Interestingly, a 
improvement in fatigue was also noticed. 
 
 
Rontalizumab, 
 
Rontalizumab is A human IgG1 monoclonal antibody targeting all known isoforms of 
human IFN-a. A Phase I trial of rontalizumab in 60 SLE patients demonstrated its safety 
and efficacy in reducing IFN signature[51]. A following a phase II study in 159 SLE patients 
with moderate severe non renal SLE showed overall similar response rates (evaluated by 
SRI and BILAG or SRI) between the treatment and placebo groups at week 24. However, 
when analysed in a post hoc analysis, Rontalizumab treatment was associated with 
improvement in signs and symptoms of SLE, flare rates and steroid burden at week 24 in a 
defined group with low signature gene expression as Metric (ISM)[52]. 
Discussion: 
 
Encouraging preliminary results of ongoing studies such as those using epratuzumab and 
blisibimod, and the recent approval of belimumab further support the concept that targeting 
B-cell remains a promising approach in the treatment of SLE. Upcoming synthetic peptides 
and new oral immunomodulator agent may also prove to be effective treatments for SLE. 
However, one should bare in mind that the huge heterogeneity of clinical response among 
SLE patients may reflect the clinical variability of the disease 
 
Whether these novel modalities are synergistic to conventional drugs, the optimal 
dosages, and duration of treatment have to be explored. Assessment tools have to be 
standardized and efficacy end points have to be appropriately defined. Post-marketing 
surveillance and registry data are also essential to evaluate the long-term safety, efficacy, 
 
and cost-effectiveness of these novel therapies. 
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Table 1. Novel biological therapies for systemic lupus erythematosus. 
 
Mechanism Agent 
Targeting surface molecules on B cells Ocrelizumab (fully humanized anti-CD20) 
Epratuzumab (fully humanized anti-CD22) 
Targeting B cell growth and survival factors Atacicept 
Blisibimod 
Tabalumab 
Toleragen molecule Abetimus sodium 
Proteasome inhibition Bortezomib 
Targeting co-stimulatory molecules AMG 557 (against B7RP-1, an inducible co-stimulator ligand) 
Targeting T cells Edratide 
Rigerimod 
Laquinimod 
Targeting cytokines — IL 6 Tocilizumab 
Sirukumab 
Targeting cytokines — type I interferons Sifalimumab 
Rontalizumab 
 
